The IGROVCDDP cisplatin-resistant ovarian cancer cell collection can be resistant to
The IGROVCDDP cisplatin-resistant ovarian cancer cell collection can be resistant to paclitaxel and choices the resistance phenotype of relapsed ovarian cancer patients after first-line platinum/taxane chemotherapy. substrate. Cisplatin level of resistance in IGROVCDDP can be multifactorial and it is mediated partly from the glutathione pathway and reduced build up of medication. Total mobile glutathione had … [Read more…]